MINNEAPOLIS, April 08, 2016 -- On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Guardian II hemostasis valves should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from March 2015 to February 2016 and distributed from April 2015 to February 2016.
The recalled products are specific lots of Model Numbers 8210 and 8211. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 26,550 devices have been manufactured, with 5,283 distributed in the United States. The condition that led to the recall may affect approximately 2.4% of recalled devices.
Vascular Solutions Inc. voluntarily initiated the recall on March 3, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S.
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
xAI Cash Burn Highlights the High Cost of Competing in Generative AI
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 



